Dilated cardiomyopathy in dialysis patients--beneficial effects of carvedilol: a double-blind, placebo-controlled trial (Q32054903)

6 July 2017

Dilated cardiomyopathy in dialysis patients--beneficial effects of carvedilol: a double-blind, placebo-controlled trial (English)

1 reference

6 July 2017

0 references

0 references

placebo-controlled trial

1 reference

1 reference

dilated cardiomyopathy

1 reference

G Cice

1

1 reference

6 July 2017

L Ferrara

2

1 reference

6 July 2017

A Di Benedetto

3

1 reference

6 July 2017

P E Russo

4

1 reference

6 July 2017

G Marinelli

5

1 reference

6 July 2017

F Pavese

6

1 reference

6 July 2017

A Iacono

7

1 reference

6 July 2017

language of work or name

English

0 references

publication date

1 February 2001

1 reference

Journal of the American College of Cardiology

6 July 2017

1 reference

6 July 2017

37

1 reference

6 July 2017

2

1 reference

6 July 2017

407-411

1 reference

Congestive heart failure in dialysis patients: prevalence, incidence, prognosis and risk factors.

6 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2901158-X

7 January 2021

The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2901158-X

7 January 2021

Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2901158-X

7 January 2021

Sympathetic overactivity in patients with chronic renal failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2901158-X

7 January 2021

Sympathetic Overactivity in Hypertensive Patients with Chronic Renal Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2901158-X

7 January 2021

Pathophysiologic and pharmacologic rationales for clinical management of chronic heart failure with beta-blocking agents

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2901158-X

7 January 2021

Efficacy of carvedilol on complex ventricular arrhythmias in dilated cardiomyopathy: double-blind, randomized, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2901158-X

7 January 2021

The pharmacokinetics of carvedilol and its metabolites after single and multiple dose oral administration in patients with hypertension and renal insufficiency

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2901158-X

7 January 2021

Time course of improvement in left ventricular function, mass and geometry in patients with congestive heart failure treated with beta-adrenergic blockade

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2901158-X

7 January 2021

Double-blind, placebo-controlled study of the long-term efficacy of carvedilol in patients with severe chronic heart failure.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2901158-X

7 January 2021

Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2901158-X

7 January 2021

Dose-response of chronic beta-blocker treatment in heart failure from either idiopathic dilated or ischemic cardiomyopathy. Bucindolol Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2901158-X

7 January 2021

A randomized trial of beta-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). CIBIS Investigators and Committees

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2901158-X

7 January 2021

Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. US Carvedilol Heart Failure Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2901158-X

7 January 2021

Medical therapy can improve the biological properties of the chronically failing heart. A new era in the treatment of heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2901158-X

7 January 2021

Effects of long-term enalapril therapy on cardiac structure and function in patients with left ventricular dysfunction. Results of the SOLVD echocardiography substudy

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2901158-X

7 January 2021

Morbidity and mortality on maintenance haemodialysis

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2901158-X

7 January 2021

10.1016/S0735-1097(00)01158-X

Identifiers

DOI

1 reference

release_m6izndyaujeozmyj4m4gmp66ue

6 July 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/m6izndyaujeozmyj4m4gmp66ue

24 November 2022

mapped directly with Wikidata item

1 reference